This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: The University of Texas System. Active years: 2017-2023.
Company Filing History:
Years Active: 2017-2023
Title: Janani Krishnamurthy: Innovator in Immunotherapy
Introduction
Janani Krishnamurthy is a prominent inventor based in Houston, TX (US). She has made significant contributions to the field of immunotherapy, particularly through her work on engineered chimeric antigen receptor (CAR) T-cells. With a total of 2 patents, her innovations are paving the way for advanced cancer treatments.
Latest Patents
Janani's latest patents focus on the human application of engineered chimeric antigen receptor (CAR) T-cells. The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are produced using electroporation in conjunction with a transposon-based integration system. This innovative approach aims to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease treatment, particularly for cancer.
Career Highlights
Janani is affiliated with the University of Texas System, where she continues to advance her research in immunotherapy. Her work is characterized by a commitment to developing effective treatments that harness the power of the immune system.
Collaborations
Janani collaborates with notable colleagues, including Hiroki Torikai and Ling Zhang. Their combined expertise enhances the research and development of innovative therapies in the field.
Conclusion
Janani Krishnamurthy is a trailblazer in the realm of immunotherapy, with her patents and research contributing significantly to cancer treatment advancements. Her dedication to innovation and collaboration exemplifies the spirit of modern scientific inquiry.